Abstract
Zileuton, a drug that inhibits the action of 5-lipoxygenase can decrease symptoms, bronchodilator use, and improve airway function in patients with mild to moderate asthma. Dosing regimens associated with greater inhibition of leukotriene production were also associated with greater improvement (ie, 600 mg four times a day or 2.4g/day). These findings support the role of leukotrienes in the pathogenesis of asthma and suggest that agents modulating their formation or activity may be of therapeuutic benefit in mild to moderate asthma.
- Copyright © 1995 by the American Academy of Pediatrics
Individual Login
Log in
You will be redirected to aap.org to login or to create your account.
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
THE EFFECT OF INHIBITION OF 5-LIPOXYGENASE BY ZILEUTON IN MILD TO MODERATE ASTHMA
Jump to section
Related Articles
Cited By...
- No citing articles found.